14094-37-2

Basic information

• Product Name: 6-AMINO-5-BROMO-1-METHYLURACIL MONOHYDRATE
• Synonyms: 6-AMINO-5-BROMO-1-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE;6-AMINO-5-BROMO-1-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE;6-AMINO-5-BROMO-1-METHYLURACIL;6-AMINO-5-BROMO-1-METHYLURACIL MONOHYDRATE;4-AMINO-5-BROMO-3-METHYLURACIL;6-AMINO-5-BROMO-1-METHYLURACIL 1-HYDRATE;6-Amino-5-bromo-1-methluracilmonohydrate;1-Methyl-5-bromo-6-aminouracil
• CAS NO: 14094-37-2
• Molecular Formula: C₅H₆BrN₃O₂
• Molecular Weight: 220.03
• Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides;Amines;Aromatics;Heterocycles
• Mol File: 14094-37-2.mol
• Article Data: 16

Chemical Properties

• Melting Point: >300°C
• Appearance: White solid
• Density: 1.868 g/cm³
• Solubility: DMSO, DMF
• Stability: Store Tightly Sealed at RT
• CAS DataBase Reference: 6-AMINO-5-BROMO-1-METHYLURACIL MONOHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMINO-5-BROMO-1-METHYLURACIL MONOHYDRATE(14094-37-2)
• EPA Substance Registry System: 6-AMINO-5-BROMO-1-METHYLURACIL MONOHYDRATE(14094-37-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 14094-37-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C5H6BrN3O2.H2O/c1-9-3(7)2(6)4(10)8-5(9)11;/h7H2,1H3,(H,8,10,11);1H2

Upstream product

• 2434-53-9 6-amino-1-methyluracil 

Downstream Products

• 55441-70-8 6-amino-1-methyl-5-(methylamino)pyrimidine-2,4-dione 
• 143958-73-0 3,7-dihydro-7-(4-methoxybenzyl)-3-methyl-1H-purine-2,6-dione 
• 56025-86-6 7-benzyl-3-methylxanthine 
• 586408-20-0 1-pivaloyloxymethyl-7-benzyl-3-methylxanthine 
• 70404-28-3 6-amino-5-(benzylamino)-1-methylpyrimidine-2,4(1H,3H)-dione 
• 131598-63-5 6-amino-5-(butylamino)-1-methylpyrimidine-2,4(1H,3H)-dione 
• 131598-62-4 6-Amino-5-ethylamino-1-methyl-1H-pyrimidine-2,4-dione 
• 125092-42-4 6-amino-1-methyl-5-(propylamino)pyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Preparation method of linagliptin for treating type II diabetes mellitus

The invention provides a preparation method of linagliptin for treating type II diabetes mellitus, which comprises the following steps: by using methylurea and ethyl cyanoacetate as raw materials, carrying out cyclization reaction to form a compound II, carrying out bromination reaction on the compound II to generate a compound III, carrying out condensation reaction on the compound III and 1-amino-2-butyne to generate a compound IV, making the compound IV, formic acid and an iodine source react in an organic solution to generate a compound V, reacting the compound V and a compound VI under the conditions of DMF and anhydrous potassium carbonate, reacting with (R)-3-Boc-aminopiperidine (VIII), and recrystallizing to obtain a pure target compound I, namely linagliptin. The invention provides a novel preparation method of linagliptin, which has the advantages of simple method, high reaction yield, avoidance of side reaction, cheap raw materials, reduction of the reaction cost, increase of the yield of the target compound, and suitableness for industrial large-scale production.

Discovery of the theobromine derivative MQS-14 that induces death of MGC-803 cells mainly through ROS-mediated mechanisms

Reactive oxygen species (ROS) play crucial roles in maintaining redox balance and regulating physiological processes, ROS levels in cancer cells are relatively higher than those in normal cells. Therefore, elevating cellular ROS levels may be a viable strategy for selective killing of cancer cells. In this work, we synthesized a series of new theobromine derivatives and evaluated their cytotoxicity against gastric cancer cells MGC-803, SGC-7901 and HGC-27. Particularly, MQS-14 potently inhibited cell growth of MGC-803, SGC-7901 and HGC-27 cells at low micromolar levels. Mechanistic studies showed that compound MQS-14 decreased cell viability of MGC-803 cells and inhibited cell division revealed by the CFDA and EdU staining assays. MQS-14 increased cellular ROS levels and activated the MAPK pathway accompanied by the decreased p-ERK and increased p-JNK expression. MQS-14 also induced DNA damage and apoptosis in MGC-803 cells. To conclude, MQS-14 induced cell death of MGC-803 cells partly through elevating cellular ROS levels.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.